Researchers find new benefits, risks in GLP-1 weight loss drugs
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
20 independently sourced, verified news trends involving GLP-1.
This hub is built from stories supported by at least four independent sources and accepted by Newsylist's verification pass. Qualifying coverage spans 2 news categories, from Jun 25, 2026 through Aug 19, 2026.
Open any card for the source list, timeline and coverage-velocity evidence. Raw detections and extractive-only records are excluded from this page.
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
Medicare now provides access to GLP-1 weight-loss drugs as utilization rates among U.S. adults reach one in eight.
Compounded GLP-1 weight‑loss drugs face mounting scrutiny as doctors and regulators flag safety concerns.
GLP‑1 weight‑loss drugs are reshaping women’s marriage prospects and job markets, while sparking warnings about unseen relationship strain.
Researchers identify existing medications, including GLP-1 drugs and nasal sprays, as potential candidates for slowing biological aging processes.
Regulators and health advisors are warning of a rare but severe risk of vision loss associated with GLP-1 weight-loss medications.
A new economic study suggests a correlation between the use of GLP-1 weight-loss drugs and a 17% reduction in employee sick leave.
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
GLP-1 weight-loss medications are seeing a massive surge in adoption, sparking debates over side effects and social disclosure.
Recent studies examine the long-term impact of discontinuing GLP-1 weight-loss medications like Ozempic and Wegovy.
Rising demand for GLP-1 weight-loss medications is straining budgets and prompting insurers and employers to limit coverage.
New oral GLP-1 receptor agonists are emerging as powerful alternatives to existing weight-loss medications in recent clinical trials.
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
Delta Air Lines is introducing new, lower-cost ticket options for business and first-class cabins that come with reduced amenities.
Medical professionals are warning patients on GLP-1 medications about increased health risks during the current heat wave.
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.